Maisa Moustafa

Dr. Maisa Moustafa


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in Molecules
Verified
Journal Article
Open access
PDF file
MSMamdouh M. Shawki
Mamdouh M. Shawki
Alaa Abdullah El-SadiequeAlaa Abdullah El-Sadieque
Alaa Abdullah El-Sadieque
SESeham Elabd
Seham Elabd
MMMaisa Moustafa
Maisa Moustafa
Cancer remains a leading cause of death worldwide, despite extraordinary progress. So, new cancer treatment modalities are needed. Tumor-treating fields (TTFs) use low-intensity, intermediate-frequency alternating electric fields with reported cancer anti-mitotic properties. Moreover, nanomedicine is a promising therapy option for cancer. Numerous cancer types have been treated with nanoparticles, but zinc oxide nanoparticles (ZnO NPs) exhibit biocompatibility. Here, we investigate the activity of TTFs, a sub-lethal dose of ZnO NPs, and their combination on hepatocellular carcinoma (HepG2), the colorectal cancer cell line (HT-29), and breast cancer cell lines (MCF-7). The lethal effect of different ZnO NPs concentrations was assessed by sulforhodamine B sodium salt assay (SRB). The cell death percent was determined by flow cytometer, the genotoxicity was evaluated by comet assay, and the total antioxidant capacity was chemically measured. Our results show that TTFs alone cause cell death of 14, 8, and 17% of HepG2, HT-29, and MCF-7, respectively; 10 µg/mL ZnO NPs was the sub-lethal dose according to SRB results. The combination between TTFs and sub-lethal ZnO NPs increased the cell death to 29, 20, and 33% for HepG2, HT-29, and MCF-7, respectively, without reactive oxygen species increase. Increasing NPs potency using TTFs can be a novel technique in many biomedical applications.

2 April 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SASamar El Achy
Samar El Achy
MMMaisa Moustafa
Maisa Moustafa
MFMohamed Fouad
Mohamed Fouad
AAAshraf Awad
Ashraf Awad
RAReham Abdelhaleem
Reham Abdelhaleem
TSThanaa Shalaby
Thanaa Shalaby
Hepatocellular carcinoma (HCC) represents a critical oncological challenge demanding innovative therapeutic interventions. miRNA has been known to play an important role in cancer inhibition to control HCC’s development and progression by regulating cell proliferation and apoptosis. The major hurdle is to deliver the miRNA at the site of tumor. Metallic nanoparticles with modified surface can be used to solve this problem. In the current study, gold-nanoparticles (Au NPs) were prepared, and their surface was modified with PEG moiety to facilitate the attachment of miRNA. For the first time, the modified gold NPs were loaded with miR-199a. Our findings revealed that, when cells treated with gold bare (80 nM) for 24 h, a low cytotoxicity was obtained (11.11 ± 2.25%). When cells treated with nanocomplex miRNA- PEG –Au NPs (80 nM) for 24 h, a significantly increased cellular cytotoxicity was obtained (55.7 ± 4.55%). Also, the prepared nanocomplex exhibits a promising potential in suppressing tumor cell proliferation and significantly enhancing apoptosis in a concentration and time dependent manner. These results underscore the transformative potential of targeted nanomaterial-based miRNA delivery as a sophisticated therapeutic modality in cancer management. In conclusion, Au NPs are excellent carriers for miRNA where they increase the cellular uptake, exerting a promising anticancer effect on HCC cells, representing a new approach in developing precision therapeutics for hepatocellular carcinoma.

16 June 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SASamar El Achy
Samar El Achy
MMMaisa Moustafa
Maisa Moustafa
MFMohamed Fouad
Mohamed Fouad
AAAshraf Awad
Ashraf Awad
RAReham Abdelhaleem
Reham Abdelhaleem
TSThanaa Shalaby
Thanaa Shalaby